These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9068934)

  • 1. Effect of sertraline on protein binding of warfarin.
    Apseloff G; Wilner KD; Gerber N; Tremaine LM
    Clin Pharmacokinet; 1997; 32 Suppl 1():37-42. PubMed ID: 9068934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.
    Tremaine LM; Wilner KD; Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():31-6. PubMed ID: 9068933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers.
    Gardner MJ; Baris BA; Wilner KD; Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():43-9. PubMed ID: 9068935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk of drug-drug interactions: a goal of rational drug development.
    Preskorn SH
    J Clin Psychiatry; 1996; 57 Suppl 1():3-6. PubMed ID: 8617709
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal.
    Riesenman C
    Pharmacotherapy; 1995; 15(6 Pt 2):84S-99S. PubMed ID: 8587855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major bleeding caused by warfarin in a genetically susceptible patient.
    Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
    Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
    Redman AR
    Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
    Hemeryck A; De Vriendt C; Belpaire FM
    Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system.
    Ereshefsky L; Riesenman C; Lam YW
    J Clin Psychiatry; 1996; 57 Suppl 8():17-24; discussion 25. PubMed ID: 8698676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo.
    Preskorn SH; Alderman J; Greenblatt DJ; Horst WD
    Psychopharmacol Bull; 1997; 33(4):659-65. PubMed ID: 9493476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.
    Xu ZH; Wang W; Zhao XJ; Huang SL; Zhu B; He N; Shu Y; Liu ZQ; Zhou HH
    Br J Clin Pharmacol; 1999 Sep; 48(3):416-23. PubMed ID: 10510155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
    Schmider J; Greenblatt DJ; von Moltke LL; Karsov D; Shader RI
    Br J Clin Pharmacol; 1997 Nov; 44(5):495-8. PubMed ID: 9384467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
    Kunze KL; Wienkers LC; Thummel KE; Trager WF
    Drug Metab Dispos; 1996 Apr; 24(4):414-21. PubMed ID: 8801056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
    Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
    Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.